ARUP Laboratories
500 Chipeta Way
Salt Lake City
Utah
84108
United States
Tel: 801-583-2787
Fax: 801-583-2712
Website: http://www.aruplab.com/
Email: webadmin@aruplab.com
88 articles about ARUP Laboratories
-
ARUP Laboratories Urges FDA to Withdraw Proposed Rule Regulating Laboratory-Developed Tests
11/29/2023
ARUP Laboratories today released the company's public comment on the FDA's proposed rule to regulate laboratory-developed tests (LDTs) as medical devices, urging the agency to withdraw the rule.
-
EU Approval of AAV5 DetectCDx™ Provides Access to Companion Diagnostic for Hemophilia A Gene Therapy
11/10/2023
ARUP Laboratories today announced that it has gained the Conformité Européenne (CE) to aid in the selection of adult patients eligible for BioMarin's new gene therapy for severe hemophilia A, valoctocogene roxaparvovec-rvox (ROCTAVIAN™).
-
FDA Approves ARUP Laboratories' AAV5 DetectCDx™, a First-Ever Companion Diagnostic Immunoassay for a Gene Therapy
6/30/2023
ARUP Laboratories announced that the U.S. Food and Drug Administration has approved AAV5 DetectCDx™ as a companion diagnostic to aid in the selection of adult patients eligible for treatment with ROCTAVIAN™.
-
ARUP Laboratories Chooses Gestalt's PathFlow® Solution for Its Strategic Digital Initiatives
4/12/2023
Gestalt Diagnostics Inc. and ARUP Laboratories announced that ARUP has selected Gestalt's award-winning PathFlow® digital platform as the solution to support its comprehensive vision for digital pathology.
-
AAV5 DetectCDx™ Kit Is First ARUP Test Developed to Support a New Therapy
9/27/2022
The European Commission's approval of a novel gene therapy for severe hemophilia A has paved the way for use of a companion diagnostic in the European Union.
-
New Executive Appointments Position ARUP Laboratories for Future Growth
5/9/2022
Effective July 1, 2022, Jonathan Genzen, MD, PhD, will become chief medical officer of ARUP Laboratories, and Adam Barker, PhD, will become chief operations officer.
-
ARUP Renames Consulting Team as ARUP Healthcare Advisory Services
3/1/2022
ARUP Laboratories has renamed its expert team of healthcare consultants as ARUP Healthcare Advisory Services.
-
ARUP Laboratories Reduces Turnaround Time on Panel Analysis by 30% with GenomOncology
7/14/2021
GenomOncology announced that ARUP Laboratories has chosen to extend its use of the GenomOncology Precision Oncology API Suite by integrating the GO Clinical Trial and Therapy Matching APIs into its current workflows to strengthen its patient care offerings.
-
ARUP Announces Retirement of CEO Sherrie L. Perkins, Appointment of President Andy Theurer to Replace Her as CEO
4/13/2021
ARUP Laboratories announced the retirement of CEO Sherrie L. Perkins, MD, PhD, effective June 30, 2021.
-
ARUP Sequencing Specimens Positive for SARS-CoV-2 to Detect the UK Variant and Other Possible Strains of the Virus
1/19/2021
ARUP Laboratories, a major provider of COVID-19 molecular diagnostic testing in Utah and nationwide, announced that it is sequencing variants of SARS-CoV-2 in specimens positive for COVID-19 to enable detection of the more contagious "United Kingdom variant" of the virus.
-
ARUP Announces the Availability of COVID-19 Saliva Testing
9/11/2020
ARUP Laboratories announced that it now offers testing to detect the virus that causes COVID-19 using saliva specimens.
-
With Antibody Testing Now Available, ARUP Provides Testing Nationwide to Help Diagnose, Monitor, and Treat COVID-19
4/28/2020
In the six weeks since ARUP Laboratories became the first clinical laboratory in Utah and one of the first in the nation to offer COVID-19 molecular diagnostic testing, ARUP has performed more than 40,000 tests in Utah alone and its tests have identified 55 percent of COVID-19-positive individuals in the state.
-
ARUP Rolls Out Coronavirus Testing
3/10/2020
ARUP Laboratories today announced the launch of its new test for the novel coronavirus. ARUP will start COVID-19 testing on March 12, 2020 . As a leading national reference laboratory, ARUP
-
FDA Files ARUP Laboratories' AAV5 CDx for Hemophilia A Gene Therapy Treatment
2/20/2020
SALT LAKE CITY , Feb. 20, 2020 /PRNewswire/ -- ARUP Laboratories announced today that the Food and Drug Administration (FDA) has filed ARUP's premarket approval application (PMA) for an AAV5 total antibody assay. The assay is intended as a companion diagnostic test for valoctocogene roxaparvovec, BioMarin's investigational gene therapy treatment for severe hemophilia A.
-
ARUP Laboratories Deploys World’s First AI-Augmented Ova and Parasite Assay
8/19/2019
ARUP Laboratories and Techcyte have developed the world’s first AI-augmented ova and parasite detection tool.
-
ARUP Finalist Twice, and Awarded Support Services Supplier of the Year by Vizient
4/17/2019
Finalist for both The Support Services Supplier of the Year Award and the Compliance and Integrity award, ultimately winning the Support Services Supplier of the Year.
-
Michael Lorimer to Lead Arup's Growing Northeast Healthcare Business
4/1/2019
Lorimer joins Arup in Boston after 17 years with company's UK office
-
Interpace Diagnostics Announces Agreement with ARUP Laboratories
12/18/2017
Interpace Diagnosticsi today announced that the Company has entered into a Laboratory Services Agreement with ARUP Laboratories, of Salt Lake City, Utah, whereby ARUP is utilizing Interpace Diagnostics as a laboratory services provider for its menu of molecular testing services.
-
ARUP Labs and Applied Spectral Imaging Bring Medical Innovation to Pathology
11/14/2017
ARUP Labs and ASI announced today they have completed a multi-year collaboration, leading to the launch of ASI's PathFusion.
-
IDbyDNA And ARUP Laboratories Introduce Explify Respiratory: Breakthrough Technology To Diagnose Pneumonia Caused By Previously Undetected Pathogens
9/19/2017